PAK4 and breast cancer: PAK4, a kinase that can phosphorylate MZF1 serine 27 in response to ErbB2 activation, is considered as a good target for the treatment of a variety of solid cancers including breast cancer, and its inhibition for this purpose has been patented by Hoffman-La Roche and Genentech [96].